Ramprasad Subramaniam, MD
Internal Medicine · Marietta, GANPI 1932128998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Johnson & Johnson at 29.2% of the total.
Across 145 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$867
- Pfizer$625
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$395
- Novartis$180
- UCB, Inc.$150
- AbbVie$114
- plus $634 from 13 others
Across 62 payments — averaging $2243.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$139K
What the payments were for
- Food & beverage$2,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 40 | $867 |
| Pfizer | 31 | $625 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $395 |
| Novartis | 10 | $180 |
| UCB, Inc. | 7 | $150 |
| AbbVie(2 entities) | 6 | $114 |
| Merck | 6 | $114 |
| Inari Medical, Inc. | 5 | $106 |
| Boehringer Ingelheim | 3 | $59 |
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Novo Nordisk | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| AstraZeneca | 2 | $35 |
| Melinta Therapeutics, LLC | 2 | $33 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Stryker | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$149
How this compares
$2,965 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Marietta
- Ebon BourneMarietta$242K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.